Arrowhead Pharmaceuticals, Inc. (ARWR)
Arrowhead Pharmaceuticals, Inc. (ARWR) is a healthcare company (biotechnology) based in the United States. The share price is $43.22, down 2.24% on the day, which values the company at $6.11B. Price as of 17 Nov 2026, 17:22 UTC, from Yahoo Finance.
Key facts
- Share price
- $43.22−2.24% today
- Market value
- $6.11B
- Funk Score
- 31/100
- Against its own history
- Above its usual priceusual price $34.49
- 200-week average
- $37.1616% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Arrowhead Pharmaceuticals, Inc. in more detail
ARWR trades at -12.0× next year's expected earnings, 13.6× sales. Measured against its own history, the price is 25% above what its usual multiples would imply ($34.49) — above its usual price. It sits 16% above its 200-week average of $37.16.
Over the last five fiscal years Arrowhead Pharmaceuticals, Inc. has compounded revenue 26.7% a year. Its Funk Score is 31 out of 100 (financial strength 2.8, profitability 0.3, growth 8.0, value 1.4, each out of 10).
In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.
2 of the superinvestors tracked here hold ARWR, including Julian and Felix Baker (0.8% of the portfolio), Brandon Haley (0.2% of the portfolio).
Superinvestors holding ARWR
2 of the investors tracked here report a position in their latest 13F filing.
- Julian and Felix Baker Baker Bros. Advisors0.81% of portfolio · $162.4M · Q2 2026
- Brandon Haley Holocene Advisors0.21% of portfolio · $90.2M · new · Q2 2026
Health Care companies of similar size
- Bausch + LombBLCO
- Amneal PharmaceuticalsAMRX
- Caris Life SciencesCAI
- ImmunovantIMVT
- Axsome TherapeuticsAXSM
- ChemedCHE
- Oruka TherapeuticsORKA
- MSA SafetyMSA
- CG OncologyCGON
- Kodiak SciencesKOD
- Lantheus HoldingsLNTH
- RadNetRDNT
Side by side:ARWR vs ORKA (Arrowhead Pharmaceuticals, Inc. vs Oruka Therapeutics)ARWR vs CHE (Arrowhead Pharmaceuticals, Inc. vs Chemed)ARWR vs AXSM (Arrowhead Pharmaceuticals, Inc. vs Axsome Therapeutics)ARWR vs MSA (Arrowhead Pharmaceuticals, Inc. vs MSA Safety)ARWR vs CGON (Arrowhead Pharmaceuticals, Inc. vs CG Oncology)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Arrowhead Pharmaceuticals, Inc. (ARWR): questions and answers
What is Arrowhead Pharmaceuticals, Inc.'s market cap?
Arrowhead Pharmaceuticals, Inc. is valued at $6.11B at a share price of $43.22.
Is ARWR overvalued or undervalued?
Against its own history, ARWR is above its usual price: the price is 25% above the $34.49 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is ARWR above its 200-week moving average?
Yes. ARWR is 16.3% above its 200-week average of $37.16. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Arrowhead Pharmaceuticals, Inc. growing?
Over the last five fiscal years Arrowhead Pharmaceuticals, Inc.'s revenue grew 26.7% a year; over ten years revenue grew 121.5% a year.
Does ARWR pay a dividend?
Arrowhead Pharmaceuticals, Inc. does not currently pay a regular dividend.
Which famous investors own ARWR?
In their latest quarterly filings, Julian and Felix Baker (0.8% of the portfolio), Brandon Haley (0.2% of the portfolio) hold ARWR. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Arrowhead Pharmaceuticals, Inc. (ARWR) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ARWR
Underlying data: Yahoo Finance; company filings with the SEC.